JP2021535167A5 - - Google Patents
Info
- Publication number
- JP2021535167A5 JP2021535167A5 JP2021511591A JP2021511591A JP2021535167A5 JP 2021535167 A5 JP2021535167 A5 JP 2021535167A5 JP 2021511591 A JP2021511591 A JP 2021511591A JP 2021511591 A JP2021511591 A JP 2021511591A JP 2021535167 A5 JP2021535167 A5 JP 2021535167A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- dosage range
- taurinamide
- response
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025088837A JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725650P | 2018-08-31 | 2018-08-31 | |
| US62/725,650 | 2018-08-31 | ||
| PCT/US2019/049266 WO2020047530A1 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088837A Division JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535167A JP2021535167A (ja) | 2021-12-16 |
| JPWO2020047530A5 JPWO2020047530A5 (https=) | 2022-09-07 |
| JP2021535167A5 true JP2021535167A5 (https=) | 2022-09-07 |
Family
ID=69643283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511591A Pending JP2021535167A (ja) | 2018-08-31 | 2019-09-03 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
| JP2025088837A Pending JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088837A Pending JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3843747A4 (https=) |
| JP (2) | JP2021535167A (https=) |
| KR (1) | KR20210054544A (https=) |
| CN (1) | CN113226325A (https=) |
| AU (1) | AU2019331913B2 (https=) |
| CA (1) | CA3111100A1 (https=) |
| WO (1) | WO2020047530A1 (https=) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
| US7151099B2 (en) * | 1998-07-31 | 2006-12-19 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases |
| GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| CN100519525C (zh) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
| JP5027369B2 (ja) * | 1999-12-06 | 2012-09-19 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
| US20080171738A1 (en) * | 2001-04-03 | 2008-07-17 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of Breast Cancer |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| CA2482687C (en) * | 2003-09-29 | 2012-11-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
| US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| WO2007020509A1 (en) * | 2005-08-15 | 2007-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
| ES2377206T3 (es) * | 2006-01-06 | 2012-03-23 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam |
| CN103118669B (zh) * | 2010-06-01 | 2016-01-13 | 盖斯特里希医药公司 | 口服药物治疗方法和组合物 |
| EP3402527B1 (en) * | 2016-01-11 | 2022-09-28 | CorMedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
| CA3018145C (en) * | 2016-03-18 | 2024-09-17 | Geistlich Pharma Ag | TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER |
| JP2021535163A (ja) * | 2018-08-28 | 2021-12-16 | コーメディクス・インコーポレーテッド | タウロリジン加水分解産物による神経芽細胞腫治療 |
-
2019
- 2019-09-03 CN CN201980072806.2A patent/CN113226325A/zh active Pending
- 2019-09-03 EP EP19854097.3A patent/EP3843747A4/en active Pending
- 2019-09-03 CA CA3111100A patent/CA3111100A1/en active Pending
- 2019-09-03 JP JP2021511591A patent/JP2021535167A/ja active Pending
- 2019-09-03 AU AU2019331913A patent/AU2019331913B2/en active Active
- 2019-09-03 WO PCT/US2019/049266 patent/WO2020047530A1/en not_active Ceased
- 2019-09-03 KR KR1020217009412A patent/KR20210054544A/ko active Pending
-
2025
- 2025-05-28 JP JP2025088837A patent/JP2025128194A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4303583T3 (fi) | Csf1r-estäjiä käytettäviksi tenosynoviaalisen jättisolukasvaimien hoidossa | |
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| ES2301575T5 (es) | Forma de dosificación farmacéutica con múltiples recubrimientos | |
| JP2021510380A5 (https=) | ||
| RU2010151428A (ru) | Пероральные составы, содержащие аналоги цитидина, и способы их использования | |
| WO2003039436A3 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
| CA2402169A1 (en) | Formulation and method for treating neoplasms by inhalation | |
| RU2008150750A (ru) | Системы введения лекарственных средств, содержащих рапамицин и его производные, которые предназначены для предупреждения и лечения сосудистых заболеваний | |
| ES3036967T3 (en) | Delayed release deferiprone tablets and methods of using the same | |
| JP2016515586A5 (https=) | ||
| JP2018526403A5 (https=) | ||
| JP2020523354A5 (https=) | ||
| RS63675B1 (sr) | Sistemi za isporuku leka i metode za lečenje raka bešike gemcitabinom | |
| JP2021535163A5 (https=) | ||
| TW201829003A (zh) | 胃腸道感染腔內治療系統 | |
| CA2486859A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
| US20160151406A1 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
| RU2005126819A (ru) | Усовершенствованное лечение опухолей | |
| JP2021535167A5 (https=) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| FI4255563T3 (fi) | 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö | |
| JPWO2020047530A5 (https=) | ||
| JPWO2020047113A5 (https=) | ||
| JPWO2020247421A5 (https=) |